News & Publications

A new paper published in the British Journal of Clinical Pharmacology sets out a roadmap for designing the next generation of system-level medicines – drugs that deliver the sweeping health benefits seen with GLP-1s such as Ozempic and Wegovy, but more effectively and without their biological trade-offs and side effects. The paper identifies necrosis, or uncontrolled cell death, as a key process driving widespread age-related decline, and positions LinkGevity’s Anti-Necrotic as a leading candidate in this emerging class of broad-spectrum, system-level therapeutics.

The article captures how our work on Anti-Necrotic™ technology is opening new frontiers in medicine and longevity science. This recognition and progress reflects the collaboration and vision of our amazing team and partners.

LinkGevity, in partnership with Lithuania’s Delta Biosciences, has been awarded funding under the UK Space Agency’s International Bilateral Fund to prepare its first-in-class Anti-Necrotic™ therapeutic for space deployment. Building on their role in NASA’s Space Health Programme, the collaboration aims to fast-track treatments against cell death and degeneration, with potential impact on astronaut health and age-related diseases on Earth.